Printer Friendly

Research and Markets: Peptic Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2018.

DUBLIN -- Dublin - Research and Markets ( has announced the addition of GlobalData's new report "Peptic Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.

Peptic Ulcer Therapeutics Market is Forecast to Show Low Growth until 2018

GlobalData estimates that the global peptic ulcer therapeutics market was worth $892.4m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% to $1,046.2m by 2018. Peptic ulcers develop due to two main factors: infection with Helicobacter pylori (H. pylori) and the long-term use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). H. pylori infection accounts for almost 85% of all peptic ulcer cases. The peptic ulcer market is well served by Proton Pump Inhibitors (PPIs), which form the majority. PPIs include omeprazole, lansoprazole, pantoprazole, Nexium (esomeprazole) and Aciphex (rabeprazole); and histamine blockers such as ranitidine, nizatidine, famotidine and cimetidine. Omeprazole is currently the most widely prescribed drug for peptic ulcers across the seven major markets. It is available as a generic and an Over-The-Counter (OTC) drug, making it cost-effective. Between 2005 and 2010, the market grew at a CAGR of 2.8%, largely due to the lack of new drug launches and the entry of OTC versions of omeprazole and lansoprazole. The patent expiry of Prevacid (lansoprazole) in the US in 2009 did not impact the market significantly due to its small patient share within the US market.

Between 2010 and 2018, the global peptic ulcer market is expected to grow at a CAGR of 2%. During this period, Nexium (esomeprazole) and Aciphex (rabeprazole), both of which are PPIs, will lose their patent exclusivity. The patent for Nexium is set to expire in the US in 2015 and in Europe and Japan in 2014 and the patent for Aciphex will expire in the US in 2013. This is likely to be marginally compensated by the entry of new products. These new drugs include Vimovo, (naproxen/esomeprazole magnesium) launched in the US in 2010 and expected to enter the European markets in 2012; Axanum (aspirin/ esomeprazole), expected to be available in Europe by 2012; and PA32540 (aspirin/omeprazole) expected to be launched in the US by 2014 and in Europe by 2015. Vimovo, Axanum and PA32540, all are fixed-dose combinations containing an NSAID and a PPI. These drugs target NSAID-induced peptic ulcers. Therefore, their entry will positively impact the NSAID-induced peptic ulcer market.

Key Topics Covered:

1 List of Tables and Figures

2 Peptic Ulcer Therapeutics - Introduction

3 Peptic Ulcer Therapeutics - Market Characterization

4 Peptic Ulcer Therapeutics - Competitive Assessment

5 Peptic Ulcer Therapeutics - Pipeline Assessment

6 Peptic Ulcer Therapeutics - Clinical Trials Mapping

7 Strategic Assessment

8 Peptic Ulcer Therapeutics - Future Players

9 Peptic Ulcer Therapeutics - Licensing and Partnership Deals

10 Peptic Ulcer Therapeutics - Appendix

Companies Mentioned

* AstraZeneca

* Pozen

For more information visit

Source: GlobalData
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 21, 2012
Previous Article:Research and Markets: Online Retailing in France 2011.
Next Article:Pan American Bank CEO Selected as Business Book Award Finalist.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters